The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol.

Published on Jul 29, 2020in International Journal of Surgery Protocols
· DOI :10.1016/J.ISJP.2020.07.003
Alona Courtney3
Estimated H-index: 3
(Imperial College London),
Rachel O'Connell9
Estimated H-index: 9
(The Royal Marsden NHS Foundation Trust)
+ 16 AuthorsRV Dave1
Estimated H-index: 1
Sources
Abstract
Abstract Introduction Approximately 55000 women in the United Kingdom are diagnosed with new breast cancer annually. Since emerging in December 2019, SARS-CoV-2 (coronavirus disease 2019, COVID-19) has become a global pandemic, affecting healthcare delivery worldwide. In response to the pandemic, multiple guidelines were issued to assist with rationalising breast cancer care. The primary aim of the B-MaP-C study is to audit and describe breast cancer management of patients newly diagnosed with breast cancer during the COVID-19 pandemic against pre-COVID-19 management practice in the UK. The implications of changes to management will be determined and the impact of a COVID-19 diagnosis on the patient’s breast cancer management will be determined. Methods and analysis This is a multi-centre collaborative audit of consecutive breast cancer patients undergoing treatment decisions during the acute and recovery phases of the COVID-19 pandemic. All patients with newly diagnosed primary breast cancer, whose treatment was decided in a multidisciplinary meeting from the 16th March 2020, are eligible for inclusion. Ethics and dissemination As this is an audit ethical approval is not required. Each participating centre is required to register the study locally and obtain local governance approvals prior to commencement of data collection. Local audit data will be available to individual participating units for governance purposes. The results of the data analysis will be submitted for publication, as well as disseminated via the ABS newsletter and a webinar. All data will be presented at national and international conferences, circumstances permitting. Registration details Each participating centre received local governance audit registration.
📖 Papers frequently viewed together
2020
9 Authors (Feng Li, ..., Zefei Jiang)
2 Citations
References25
Newest
#1Lennard Y W Lee (University of Birmingham)H-Index: 6
#2Jean-Baptiste Cazier (University of Birmingham)H-Index: 39
Last. Gary Middleton (University of Birmingham)H-Index: 50
view all 39 authors...
Summary Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with can...
311 CitationsSource
#1A.M. Brunt (Keele University)H-Index: 12
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. John R Yarnold (The Royal Marsden NHS Foundation Trust)H-Index: 1
view all 46 authors...
Summary Background We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial. Methods FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring h...
103 CitationsSource
#1Perrine Vuagnat (Curie Institute)H-Index: 3
#2Maxime Frelaut (Curie Institute)H-Index: 4
Last. François-Clément BidardH-Index: 50
view all 17 authors...
BACKGROUND: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). METHODS: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and trea...
32 CitationsSource
Background The COVID-19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVID-19. Methods A global expert response study was conducted to elicit projections for the proportion of elective surgery that would be cancelled or postponed during the 12 weeks of peak disruption. A Bayesian β-regression model was used to estimate 12-week cancellati...
327 CitationsSource
#1Raghavan Vidya (University of Birmingham)H-Index: 3
#2Isabel T. Rubio (University of Navarra)H-Index: 23
Last. Hilton BeckerH-Index: 4
view all 7 authors...
The onset of the COVID-19 pandemic has changed the face of the treatment of breast cancer and breast reconstruction globally. Mastectomy with immediate implant-based breast reconstruction was on the rise due to advances in meshes and implants. However, due to the prioritisation of the critically ill and diversion of the work force, breast cancer treatment has drastically changed. This is an opinion paper written by the authors with experience and importance in the scenario of breast reconstructi...
1 CitationsSource
#1Charlotte E Coles (University of Cambridge)H-Index: 4
#1Charlotte E. Coles (University of Cambridge)H-Index: 39
Last. Sofia Rivera (Université Paris-Saclay)H-Index: 13
view all 17 authors...
101 CitationsSource
#1Marios Konstantinos Tasoulis (The Royal Marsden NHS Foundation Trust)H-Index: 11
#2Nicola Roche (The Royal Marsden NHS Foundation Trust)H-Index: 9
Last. Fiona MacNeill (The Royal Marsden NHS Foundation Trust)H-Index: 16
view all 3 authors...
9 CitationsSource
#1Joris van de Haar (NKI-AVL: Netherlands Cancer Institute)H-Index: 4
#2L.R. Hoes (NKI-AVL: Netherlands Cancer Institute)H-Index: 5
Last. Emile E. Voest (NKI-AVL: Netherlands Cancer Institute)H-Index: 39
view all 21 authors...
The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have org...
128 CitationsSource
The first death from covid-19 has been recorded in the UK, while the death toll across the world has exceeded 3300, with China, South Korea, Italy, and Iran having the highest numbers. The UK patient, who was described as “older” and with underlying health conditions, had been “in and out of hospital for non-coronavirus reasons” before being tested and found positive for the virus. As at 6 March more than 20 000 people had been tested for covid-19 in the UK, of whom 163 have been found positive....
10 CitationsSource
#1Patrick J. Lillie (University of Hull)H-Index: 17
#2Anda Samson (University of Hull)H-Index: 3
Last. Matthias L. Schmid (Newcastle upon Tyne Hospitals NHS Foundation Trust)H-Index: 15
view all 15 authors...
82 CitationsSource
Cited By2
Newest
#1Rajiv Dave (University of Manchester)H-Index: 14
#1RV Dave (University of Manchester)H-Index: 3
view all 22 authors...
The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Of 3776 patients (from 64 UK units) in the st...
Source
#1T Gathani (University of Oxford)H-Index: 9
#2Gill ClaytonH-Index: 1
Last. Kieran Horgan (St James's University Hospital)H-Index: 36
view all 4 authors...
Delays in cancer diagnosis and treatment due to the COVID-19 pandemic is a widespread source of concern, but the scale of the challenge for different tumour sites is not known. Routinely collected NHS England Cancer Waiting Time data were analysed to compare activity for breast cancer in the first 6 months of 2020 compared to the same time period in 2019. The number of referrals for suspected breast cancer was 28% lower (N = 231,765 versus N = 322,994), and the number of patients who received th...
3 CitationsSource